Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves first treatment targeting Demodex ➤ Phase 1 study compares mechanical dry eye treatment to drop therapy ➤ Topical gene therapy for rare ocular surface condition ➤ Glaucoma drug licensed for commercialization in U.S. ➤ ASCRS news and events
➤ Study: low-dose atropine doesn’t slow myopia progression ➤ Adverse events reported after use of FDA-approved geographic atrophy drug ➤ Phase 1 data for synthetic cannabinoid being investigated for glaucoma ➤ Enrollment complete in study evaluating topical diabetic retinopathy therapy ➤ Enrollment update for Phase 2b trial that could reduce AMD treatment burden ➤ ASCRS news and events
➤ Phase 1/2 trial to evaluate intravitreal implant to delay cataract progression ➤ Update from Phase 1/2 proof-of-concept trial for chronic TED treatment ➤ First patient dosed for investigational, oral geographic atrophy treatment ➤ Pediatric study for pain, inflammation treatment following ocular surgery ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Enrollment complete in MIGS pivotal trial ➤ Acquisition of dry eye drop ➤ Two-year results post-cilio-scleral glaucoma procedure ➤ Positive topline results from Phase 2 study of retinitis pigmentosa treatment ➤ ASCRS news and events
➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events
➤ Positive topline results in Phase 3 clinical trial for allergic conjunctivitis treatment ➤ Phase 1b topline data on investigational dry eye drop ➤ First patients dosed in Phase 1b/2 trial for Wnt agonist antibody ➤ Study: U.S. prevalence of diabetic retinopathy ➤ ASCRS news and events
➤ Cataract surgery survey results ➤ FDA approves first non-degradable, synthetic tissue for ophthalmic surgery ➤ New cyclosporine ophthalmic solution approved for dry eye ➤ Results from Phase 2b study of drug-eluting contact lens ➤ 12-month topline data for intravitreal implant in wet AMD trial ➤ AAV capsid licensed for ocular gene therapy indication ➤ ASCRS news and events
➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events
➤ FDA approves dry eye drop targeting tear evaporation ➤ Topline results from Phase 3 trial of eye drops for DME ➤ Investigational intravitreal gene therapy program introduced for geographic atrophy ➤ Phase 1 study for periocular drug for wet AMD and DME begins ➤ Commercial rights for uveitis treatment acquired ➤ ASCRS news and events